NO20016114L - Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 - Google Patents
Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1Info
- Publication number
- NO20016114L NO20016114L NO20016114A NO20016114A NO20016114L NO 20016114 L NO20016114 L NO 20016114L NO 20016114 A NO20016114 A NO 20016114A NO 20016114 A NO20016114 A NO 20016114A NO 20016114 L NO20016114 L NO 20016114L
- Authority
- NO
- Norway
- Prior art keywords
- preparations
- methods
- carrier protein
- atp binding
- cartridge carrier
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 title 1
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 title 1
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 title 1
- 235000012000 cholesterol Nutrition 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Wood Science & Technology (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 | |
| PCT/US2000/016765 WO2000078972A2 (en) | 1999-06-18 | 2000-06-16 | Regulation with binding cassette transporter protein abc1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20016114D0 NO20016114D0 (no) | 2001-12-14 |
| NO20016114L true NO20016114L (no) | 2002-02-12 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016121A NO20016121L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
| NO20016114A NO20016114L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20016121A NO20016121L (no) | 1999-06-18 | 2001-12-14 | Preparater og fremgangsmåter for å öke kolesterolutströmning og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1218515B1 (no) |
| JP (4) | JP2003506097A (no) |
| KR (2) | KR100476519B1 (no) |
| CN (2) | CN100513570C (no) |
| AR (2) | AR024391A1 (no) |
| AT (1) | ATE422545T1 (no) |
| AU (3) | AU5743400A (no) |
| BR (2) | BR0011696A (no) |
| CA (2) | CA2375787C (no) |
| DE (1) | DE60041545D1 (no) |
| HK (2) | HK1046708A1 (no) |
| IL (2) | IL147022A0 (no) |
| MX (2) | MXPA01013175A (no) |
| NO (2) | NO20016121L (no) |
| NZ (3) | NZ531401A (no) |
| SG (2) | SG121852A1 (no) |
| TR (2) | TR200200440T2 (no) |
| TW (2) | TWI259205B (no) |
| WO (2) | WO2000078972A2 (no) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| JP4726302B2 (ja) | 1999-03-15 | 2011-07-20 | ユニバーシティ オブ ブリティッシュ コロンビア | Ａｂｃ１ポリペプチドおよびコレステロール水準を調節する方法と試薬 |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| WO2001015676A2 (en) * | 1999-09-01 | 2001-03-08 | University Of British Columbia | Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| NZ522360A (en) | 2000-05-02 | 2004-12-24 | Aventis Pharma Sa | Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2003004692A2 (en) * | 2001-07-03 | 2003-01-16 | Xenon Genetics, Inc. | Screening processes for agents modulating cholesterol levels |
| CA2463395A1 (en) * | 2001-10-12 | 2003-04-24 | Grelan Pharmaceutical Co., Ltd. | Therapeutic agents for low hdl-cholesterolemia |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| JP5082033B2 (ja) | 2001-12-21 | 2012-11-28 | エグゼリクシス パテント カンパニー エルエルシー | Ｌｘｒのモジュレーター |
| WO2003060078A2 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| EP1648408A4 (en) | 2003-07-23 | 2006-11-29 | Exelixis Inc | AZEPINE DERIVATIVES AS PHARMACEUTICAL AGENTS |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| HUE045710T2 (hu) | 2005-05-18 | 2020-01-28 | Ablynx Nv | Javított, alfa tumor nekrózis faktor elleni nanobodies |
| SI2444424T1 (sl) | 2005-05-20 | 2018-10-30 | Ablynx N.V. | Izboljšana protitelesa (TM) za zdravljenje z agregacijo posredovanih motenj |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2008062830A1 (fr) | 2006-11-24 | 2008-05-29 | Hykes Laboratories Llc | Composé de spiroquinone et composition pharmaceutique |
| WO2008074840A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| CA2673331A1 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| CN101970490A (zh) | 2007-11-27 | 2011-02-09 | 埃博灵克斯股份有限公司 | 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽 |
| EP2247616A2 (en) | 2008-03-05 | 2010-11-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CN102056945A (zh) | 2008-04-07 | 2011-05-11 | 埃博灵克斯股份有限公司 | 针对Notch途径的单可变结构域 |
| US10005830B2 (en) | 2009-03-05 | 2018-06-26 | Ablynx N.V. | Antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| JP5753838B2 (ja) * | 2009-03-31 | 2015-07-22 | ザ ジェネラル ホスピタル コーポレイション | コレステロール関連障害の治療におけるｍｉｒ−３３マイクロｒｎａの調節 |
| CN105399828B (zh) | 2009-04-10 | 2021-01-15 | 埃博灵克斯股份有限公司 | 用于治疗il-6r相关疾病和病症的改进的针对il-6r的氨基酸序列和包含其的多肽 |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| EA202092589A3 (ru) | 2010-11-08 | 2021-06-30 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| JP2014525736A (ja) | 2011-06-23 | 2014-10-02 | アブリンクス エン．ヴェー． | ＩｇＥに対する免疫グロブリン単一可変ドメイン |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| SG11201408347UA (en) | 2012-06-14 | 2015-01-29 | Ambrx Inc | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| WO2014144037A1 (en) | 2013-03-15 | 2014-09-18 | Bristol-Myers Squibb Company | Lxr modulators |
| JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| WO2017089618A1 (en) | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| WO2018050833A1 (en) | 2016-09-15 | 2018-03-22 | Ablynx Nv | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| IL266506B2 (en) | 2016-11-16 | 2025-05-01 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| TW202417517A (zh) | 2017-06-02 | 2024-05-01 | 德商麥克專利有限公司 | 與ｍｍｐ１３結合之免疫球蛋白 |
| KR102740376B1 (ko) | 2017-06-02 | 2024-12-09 | 메르크 파텐트 게엠베하 | Adamts5, mmp13 및 아그레칸 결합성 폴리펩타이드 |
| CA3063293A1 (en) | 2017-06-02 | 2018-12-06 | Merck Patent Gmbh | Adamts binding immunoglobulins |
| TW202413408A (zh) | 2017-06-02 | 2024-04-01 | 比利時商艾伯林克斯公司 | 結合聚集蛋白聚糖之免疫球蛋白 |
| EP4114424A4 (en) * | 2020-03-06 | 2024-07-03 | Endolytix Technology, Inc. | COMPOSITIONS AND METHODS FOR TREATING INTRACELLULAR BACTERIAL INFECTIONS |
| CN115433733A (zh) | 2021-06-04 | 2022-12-06 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| EP4556022A1 (en) | 2022-07-14 | 2025-05-21 | Bio-Thera Solutions, Ltd. | Anti-nectin-4 antibody and use thereof |
| TW202423965A (zh) | 2022-07-27 | 2024-06-16 | 比利時商艾伯霖克斯公司 | 與新生兒fc受體的特定表位結合之多肽 |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| TW202511291A (zh) | 2023-09-11 | 2025-03-16 | 丹麥商諾佛 儂迪克股份有限公司 | 抗ｉｌ－６結構域之抗體 |
| US20250129145A1 (en) | 2023-09-22 | 2025-04-24 | Ablynx N.V. | Bi- and multivalent albumin binders |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ522360A (en) * | 2000-05-02 | 2004-12-24 | Aventis Pharma Sa | Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses |
-
2000
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active Expired - Fee Related
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Application Discontinuation
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-06-16 HK HK02108234.7A patent/HK1046708A1/zh unknown
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/xx unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/xx unknown
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Application Discontinuation
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Ceased
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
-
2001
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20016114L (no) | Preparater og fremgangsmåter for å öke kolesterolutströmming og heve HDL ved anvendelse av ATP-bindingskassett-transportörprotein ABC1 | |
| NO20020779L (no) | Fremgangsmåter, preparater og sett for å fremme helbredelse ved skader på sentralnervesystemet | |
| NO20014657L (no) | Preparater og fremgangsmåter for å påvirke nivåene av high density lipoprotein (HDL)-kolesterol og apolipoprotein A1, verylow density lipoprotein (VLDL)-kolesterol og low densitylipoprotein (LDL)-kolesterol | |
| AU3041100A (en) | Binding of antibody fragments to solid supports | |
| NO20030167L (no) | Fremgangsmåte og system for å forenkle transaksjoner ved trådlös e-handel | |
| NO20013193L (no) | Fremgangsmåte og kit for å ekstrahere prionprotein | |
| NO995164D0 (no) | Preparat for å kontrollere skadelige bioorganismer og fremgangsmåte for å kontrollere skadelige bioorganismer ved anvendelse derav | |
| NO20005632L (no) | Antistoffer mot CD23, derivater derav og deres terapeutiske anvendelse | |
| NO20024577D0 (no) | Fremgangsmåte for behandling ved å bruke ligand-immunogene konjungater | |
| NO982296D0 (no) | Triaromatiske forbindelser, preparater inneholdende disse og deres anvendelse | |
| AU5136300A (en) | Waiting prior to engaging in automated services | |
| NO20025627L (no) | Fremgangsmåter og sammensetninger for å behandle hepatitt C virus | |
| NO20014605L (no) | Humane antistoff som binder human IL-12 samt fremgangsmåter ved fremstilling derav | |
| AU1221201A (en) | Antisense modulation of y-box binding protein 1 expression | |
| IS6096A (is) | Latar fyrir LFA-1 bindingu við ICAM og notkun á þeim | |
| AUPP856399A0 (en) | Improved compounds for protein binding | |
| AU2743400A (en) | Nucleic-acid binding proteins | |
| NO20010464L (no) | FremgangsmÕter og preparater for behandling av gastro- øsofagealt-reflukssyndrom | |
| DK0867192T3 (da) | Kombinationspræparat til anvendelse ved demens | |
| AU143283S (en) | Push to close latch | |
| NO20022057D0 (no) | Fremgangsmåte og sammensetning for å behandle lungesykdommer | |
| NO993354L (no) | Voksholdige preparater | |
| AU6841300A (en) | Human antibodies or fragments thereof binding to hla-cw6 | |
| AU3452700A (en) | Antibodies to placental protein 13 | |
| DK1192163T3 (da) | Dithiepino[6,5-b]pyriner, beslægtede præparater og fremgangsmåder |